While TGF-β1 suppresses PPARγ expression in 3T3-L1 adipocytes (Xing et al., 1997), FAO is increased with TGF-β1 treatment in MCF-7 (Liu et al., 2020), Hep3B (Soukupova et al., 2021), and gastric cancer cells (Li et al., 2023), and with TGF-β2 treatment in cervical cancer cells (Corbet et al., 2020). The gene discussed is TGFB1; the disease is cervical cancer.